Skip to content
value.today
Pharmanutra S.p.A. logo

Pharmanutra S.p.A.

PHN.MI
$593 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$148 M
For year ending December-2025
Net income
$23 M
15.2% margin
Official annual report (ESEF)
Employees
—

Pharmanutra S.p.A. in brief

Pharmanutra S.p.A. is a listed company in the Pharmaceutical industry, based in Italy. Its last known market value was $593 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $148 M and a net profit of $23 M, about 15 cents of profit for every dollar of sales. Its shares trade under the symbol PHN.MI (Borsa Italiana).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Pharmanutra S.p.A. timeline

2 events, 2003–2015
  1. 2003
  2. 🏁
    · approximate
    Incorporated as Pharmanutra S.P.A.
  3. 2015
  4. •
    Legal Entity Identifier issued
    LEI 815600F8217BC7733697 registered.

Events of Pharmanutra S.p.A. from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$232 M$463 M$695 M$927 M20202021202220232024

World rank over time

▲ up 3,126 places since 2020
2020-01-01: #14693#14,69320202021-01-01: #11628#11,62820212022-01-07: #10281#10,28120222022-12-25: #10833#10,83320222023-07-30: #11047#11,04720232024-01-05: #11567#11,5672024

Rank in Italy: #127 (Jan 2020) · #100 (Jan 2021) · #95 (Jan 2022) · #94 (Dec 2022) · #96 (Jul 2023) · #93 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
15.2%
Operating margin
26.0%
Return on equity
27.0%
Liabilities / assets
43.1%
Revenue growth
+18.8%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2024: revenue $125M, net income $18M$125MFY24Fiscal year ending Dec 2025: revenue $148M, net income $23M$148MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$148M+18.8%$39M$23M15.2%
Dec 2024$125M—$34M$18M14.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025—$4M—$2356.25—
Dec 2024—$5M—$1872.19—

Annual results

Revenue
$148 M
Operating income
$39 M
Net income
$23 M

For year ending December-2025 · source: official annual report (ESEF)

Balance sheet

Total assets
$147 M
Total liabilities
$63 M
Total equity
$84 M

As of December-2025

Mutual funds holding Pharmanutra S.p.A.#

32 funds hold shares worth $12 M. Since their previous reports 11 added shares and 5 sold, buying $0 M net.
Mutual funds holding Pharmanutra S.p.A.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors25,603$2 M—<0.01%+1.2%Jul 31, 2026
🇺🇸 Polar Capital International Small Company FundPolar Capital LLP18,289$2 M—1.4%−30%Jun 30, 2026
🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors13,498$1 M—<0.01%no changeJul 31, 2026
🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP12,191$1 M—0.02%+26%Jul 31, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP10,709$1 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard International Dividend Appreciation Index FundThe Vanguard Group, Inc.7,159$1 M—<0.01%−2.0%Jul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP7,099$1 M—0.01%+122%Jul 31, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP4,906$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust4,102$0 M—<0.01%+127%May 31, 2026
🇺🇸 Old Westbury Small & Mid Cap Strategies FundBessemer Investment Management LLC3,614$0 M—<0.01%+293%Jul 31, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP3,450$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP2,475$0 M—<0.01%no changeJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC2,128$0 M—<0.01%−37%Jun 30, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP1,858$0 M—<0.01%no changeJul 31, 2026
🇺🇸 International Small Cap Growth PortfolioDimensional Fund Advisors LP1,151$0 M—0.03%no changeJul 31, 2026
🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC1,010$0 M—<0.01%+5.3%Jul 31, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP928$0 M—<0.01%no changeJul 31, 2026
🇺🇸 SIT International Equity FundSEI INVESTMENTS MANAGEMENT CORPORATION885$0 M—<0.01%newJun 30, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC826$0 M—0.02%no changeJun 30, 2026
🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP861$0 M—<0.01%no changeJul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP668$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP651$0 M—0.01%+27%Jul 31, 2026
🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc.582$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP588$0 M—<0.01%+55%Jul 31, 2026
🇺🇸 iShares MSCI Europe Small-Cap ETFBlackRock Fund Advisors400$0 M—0.02%−3.8%Jul 31, 2026
🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust325$0 M—0.01%+16%May 31, 2026
🇺🇸 Avantis International Equity FundAmerican Century ETF Trust280$0 M—<0.01%newMay 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC268$0 M—0.02%no changeJun 30, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation227$0 M—<0.01%no changeJun 30, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC161$0 M—<0.01%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc.127$0 M—<0.01%−2.3%Jun 30, 2026
🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP61$0 M—<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 32 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Ownership and subsidiaries

Source: GLEIF
Pharmanutra S.p.A. directly owns 1 registered entity:

Pharmanutra S.p.A. scorecard#

Passes 5 of the 5 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 2
    • ✓Revenue grew in the newest year18.8%Revenue up 18.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year2356.25 vs 1872.19Diluted EPS 2356.25 in fiscal 2025 against 1872.19 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 3
    • ✓Profitable in the newest year$23 MNet income $23 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median26.0%26.0% against Pharmaceutical's median of 1.8% (74 companies).
    • ✓Return on equity above 15%30.4%30.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (esef), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Pharmanutra S.p.A.'s statements, beside the median of Pharmaceutical.

Pharmanutra S.p.A.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin26.0%1.8%
Net margin15.2%-1.5%
Return on equity30.4%-0.9%
Revenue growth18.8%7.3%

Margins, returns, growth, debt and cash flow over 4 years.

Pharmanutra S.p.A.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Pharmanutra S.p.A.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue132115100836856
Operating income343126242016
Interest and finance income1.01.40.90.50.20.1
Interest expense and finance costs1.11.61.00.20.00.1
Income before tax302723231913
Income tax1011108.45.0−0.8
Income from continuing operations201713151414
Net income including minority interests201713151414
Minority interests' share of net income0.10.1————
Net income attributable to shareholders2017————
Earnings per share, diluted2,090.001,730.001,330.001,560.001,420.001,450.00
Dividends per share1.00—0.80———
Balance sheet
Cash and cash equivalents191519222916
Receivables252219221715
Inventory8.96.98.25.32.91.9
Current assets736559595640
Property, plant and equipment242626178.44.8
Other intangible assets242323225.55.2
Non-current assets525254411611
Total assets1251171121007152
Accounts payable201616179.87.2
Current liabilities312728261711
Non-current liabilities232830239.52.8
Total liabilities5455————
Shareholders' equity716254514538
Minority interests−0.1−0.0————
Total equity716254514538
Total liabilities and equity1251171121007152
Cash-flow statement
Depreciation and amortization3.93.93.11.31.42.3
Cash from operating activities——12172012
Capital expenditure−3.1−4.2−13−26−5.0−1.7
Cash from investing activities−3.4−2.2−15−27−5.5−0.6
Dividends paid−9.6−8.2−7.7−6.9−6.5−4.5
Cash from financing activities−13−22−0.51.9−1.9−8.5
Change in cash3.1−3.4−3.1−7.4——
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Pharmanutra S.p.A. compares in Pharmaceutical

  • Revenue$148 M · higher than 25% of 324
  • Net margin15.2% · higher than 73% of 313
  • Revenue growth18.8% · higher than 75% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Pharmanutra S.p.A.🇮🇹$593 M—15.2%+18.8%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 15, 2026

Figures from Official annual report (ESEF), value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Pharmanutra S.p.A.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Pharmanutra S.p.A.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Pharmanutra S.p.A.? Suggest a correction